Biomarkers in Neurodegenerative Diseases: A Bibliometric Analysis Using VOSviewer
Keywords:
Alzheimer's Disease; Parkinson's Disease; Neurodegeneration; Bibliometric Analysis; VOSviewer, Biomarkers
Abstract
The accurate and timely diagnosis of neurodegenerative diseases is a major challenge, driving considerable efforts to identify biomarkers that can detect presence of disease, progression and therapeutic response. A bibliometric analysis of the literature on biomarker research in relation to Parkinson’s disease, Alzheimer’s disease, and more neurodegenerative disorders is conducted in this study to trace the intellectual structure, working groups, and thematic development of the research. A dataset of 1,431 publications from 2010–2025 was analyzed using bibliometric and visual analysis techniques in VOS viewer. The analysis of co-authorship demonstrated that Swedish establishments, especially the Sahlgrenska Academy and Skan University Hospital dominate the research market, with Henrik Zetterberg (1, 203 citations) and Kaj Blennow (1, 134 citations) being the most influential authors. The United States was had the maximum number of publications (452 documents, 22,101 citations), then the United Kingdom and Sweden. The most cited paper was Dammer (2022) on multi-platform proteomic analysis of Alzheimer CSF and plasma biomarkers (2,293 citations). Thematic analysis showed a chronological shift from CSF-based protein markers and biomarker ratios (2010–2015) through neuroinflammatory markers and microRNAs (2015–2020) toward blood-based alternatives, digital biomarkers, and multi-modal diagnostic frameworks (2020–2025). The findings highlight the need for protocol standardisation across studies, increased collaboration with underrepresented regions, and continued development of blood-based and minimally invasive diagnostic tools. The paper has practical implications to researchers who want to collaborate and future trends in neurodegenerative biomarker studies.
References
Bermejo-Pareja, F., Antequera, D., Vargas, T., Molina, J. A., & Carro, E. (2010). Saliva levels of Abeta1-42 as potential biomarker of Alzheimer’s disease: a pilot study. BMC Neurology, 10(1), 108. https://doi.org/10.1186/1471-2377-10-108
Parnetti, L., Chiasserini, D., Bellomo, G., Giannandrea, D., De Carlo, C., Qureshi, M. M., Ardah, M. T., Varghese, S., Bonanni, L., Borroni, B., Tambasco, N., Eusebi, P., Rossi, A., Onofrj, M., Padovani, A., Calabresi, P., & El-Agnaf, O. M. A. (2011). Cerebrospinal fluid Tau/α-synuclein ratio in Parkinson’s disease and degenerative dementias†‡. Movement Disorders, 26(8), 1428–1435. https://doi.org/10.1002/MDS.23670
Wagshal, D., Sankaranarayanan, S., Guss, V., Hall, T., Berisha, F., Lobach, I., Karydas, A., Voltarelli, L., Scherling, C., Heuer, H. W., Tartaglia, M. C., Miller, Z. A., Coppola, G., Ahlijanian, M. K., Soares, H., Kramer, J. H., Rabinovici, G. D., Rosen, H. J., Miller, B. L., … Boxer, A. L. (2015). Divergent CSF τ alterations in two common tauopathies: Alzheimer’s disease and progressive supranuclear palsy. Journal of Neurology, Neurosurgery, and Psychiatry, 86(3), 244–250. https://doi.org/10.1136/JNNP-2014-308004
Toledo, J. B., Korff, A., Shaw, L. M., Trojanowski, J. Q., & Zhang, J. (2013). CSF α-synuclein improves diagnostic and prognostic performance of CSF tau and Aβ in Alzheimer’s disease. Acta Neuropathologica, 126(5), 683–697. https://doi.org/10.1007/S00401-013-1148-Z
Shill, H. A., Shill, H. A., Hentz, J. G., Caviness, J. N., Driver-Dunckley, E., Jacobson, S. A., Jacobson, S. A., Belden, C., Sabbagh, M. N., Sabbagh, M. N., Beach, T. G., & Adler, C. H. (2016). Unawareness of Hyposmia in Elderly People With and Without Parkinson’s Disease. Movement Disorders Clinical Practice, 3(1), 43–47. https://doi.org/10.1002/MDC3.12220
Skogseth, R., Skogseth, R., Hortobágyi, T., Hortobágyi, T., Soennesyn, H., Chwiszczuk, L. J., Ffytche, D., Rongve, A., Ballard, C., Ballard, C., Aarsland, D., & Aarsland, D. (2017). Accuracy of Clinical Diagnosis of Dementia with Lewy Bodies versus Neuropathology. Journal of Alzheimer’s Disease, 59(4), 1139–1152. https://doi.org/10.3233/JAD-170274
Starhof, C., Hejl, A.-M., Heegaard, N. H. H., Carlsen, A., Burton, M., Lilje, B., & Winge, K. (2018). The biomarker potential of cell‐free microRNA from cerebrospinal fluid in Parkinsonian Syndromes. Movement Disorders, 34. https://doi.org/10.1002/mds.27542
Dichev, V. D., Kazakova, M., & Sarafian, V. (2020). YKL-40 and neuron-specific enolase in neurodegeneration and neuroinflammation. Reviews in The Neurosciences, 31(5), 539–553. https://doi.org/10.1515/REVNEURO-2019-0100
Chiu, M.-J., Yang, S.-Y., Chen, T.-F., Lin, C.-H., Yang, F.-C., Chen, W.-P., Zetterberg, H., Zetterberg, H., Blennow, K., & Blennow, K. (2021). Synergistic Association between Plasma Aβ1-42 and p-tau in Alzheimer’s Disease but Not in Parkinson’s Disease or Frontotemporal Dementia. ACS Chemical Neuroscience, 12(8), 1376–1383. https://doi.org/10.1021/ACSCHEMNEURO.1C00010
Scaroni, F., Visconte, C., Serpente, M., Golia, M. T., Gabrielli, M., Huiskamp, M., Hulst, H. E., Carandini, T., De Riz, M., Pietroboni, A. M., Rotondo, E., Scarpini, E., Galimberti, D., Teunissen, C. E., van Dam, M., de Jong, B. A., Fenoglio, C., & Verderio, C. (2022). miR-150-5p and let-7b-5p in Blood Myeloid Extracellular Vesicles Track Cognitive Symptoms in Patients with Multiple Sclerosis. Cells, 11(9), 1551. https://doi.org/10.3390/cells11091551
Cavedoni, S., Chirico, A., Pedroli, E., Cipresso, P., & Riva, G. (2020). Digital Biomarkers for the Early Detection of Mild Cognitive Impairment: Artificial Intelligence Meets Virtual Reality. Frontiers in human neuroscience, 14, 245. https://doi.org/10.3389/fnhum.2020.00245
Kovac, D., Novakova, L., Mekyska, J., Novotny, K., Brabenec, L., Klobusiakova, P., & Rektorova, I. (2025). Digital speech biomarkers for assessing cognitive decline across neurodegenerative conditions. Computers in biology and medicine, 198(Pt B), 111251. https://doi.org/10.1016/j.compbiomed.2025.111251
Blennow, K., Hampel, H., Weiner, M., & Zetterberg, H. (2010). Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nature Reviews Neurology, 6(3), 131–144. https://doi.org/10.1038/nrneurol.2010.4
Brinkmalm, A., Brinkmalm, G., Honer, W. G., Frölich, L., Hausner, L., Minthon, L., … Zetterberg, H. (2014). SNAP-25 is a promising novel cerebrospinal fluid biomarker for synapse degeneration in Alzheimer’s disease. Molecular Neurodegeneration, 9, 53. https://doi.org/10.1186/1750-1326-9-53
Frisoni, G. B., Fox, N. C., Jack, C. R., Scheltens, P., & Thompson, P. M. (2010). The clinical use of structural MRI in Alzheimer disease. Nature Reviews Neurology, 6(2), 67–77. https://doi.org/10.1038/nrneurol.2009.215
Gaetani, L., Blennow, K., Calabresi, P., Di Filippo, M., Parnetti, L., & Zetterberg, H. (2019). Neurofilament light chain as a biomarker in neurological disorders. Journal of Neurology, Neurosurgery & Psychiatry, 90(8), 870–881. https://doi.org/10.1136/jnnp-2018-320106
Hardy, J., & Selkoe, D. J. (2002). The amyloid hypothesis of Alzheimer’s disease: Progress and problems on the road to therapeutics. Science, 297(5580), 353–356. https://doi.org/10.1126/science.1072994
Jack, C. R., Bennett, D. A., Blennow, K., Carrillo, M. C., Dunn, B., Haeberlein, S. B., … Silverberg, N. (2018). NIA-AA research framework: Toward a biological definition of Alzheimer’s disease. Alzheimer’s & Dementia, 14(4), 535–562. https://doi.org/10.1016/j.jalz.2018.02.018
Janelidze, S., Mattsson, N., Palmqvist, S., Smith, R., Beach, T. G., Serrano, G. E., … Hansson, O. (2020). Plasma P-tau181 in Alzheimer’s disease. Nature Medicine, 26(3), 379–386. https://doi.org/10.1038/s41591-020-0755-1
Liu, C.-C., Kanekiyo, T., Xu, H., & Bu, G. (2013). Apolipoprotein E and Alzheimer disease: Risk, mechanisms and therapy. Nature Reviews Neurology, 9(2), 106–118. https://doi.org/10.1038/nrneurol.2012.263
Lowes, H., Pyle, A., Duddy, M., Hudson, G., & Chinnery, P. F. (2019). Reduced circulating cell-free mitochondrial DNA is associated with neurodegeneration. Annals of Clinical and Translational Neurology, 6(6), 1094–1102. https://doi.org/10.1002/acn3.782
Lowes, H., Pyle, A., Duddy, M., Hudson, G., & Chinnery, P. F. (2020). Cell-free mitochondrial DNA in disease. Clinical Chemistry, 66(2), 249–256. https://doi.org/10.1093/clinchem/hvz029
Mastrangelo, A., Rossi, M., Baiardi, S., Zenesini, C., Capellari, S., & Parchi, P. (2024). α-Synuclein seed amplification assay parameters correlate with disease stage and dementia in Lewy body disease. Acta Neuropathologica, 147, 45–60. https://doi.org/10.1007/s00401-023-02658-7
Pedersen, A. L., Eriksson, J. E., Nilsson, J., Bäckström, D., Blennow, K., Zetterberg, H., & Svenningsson, P. (2023). Inflammatory biomarker panels identified using proximity extension assays distinguish Parkinson’s disease and Alzheimer’s disease. Movement Disorders, 38(4), 612–624. https://doi.org/10.1002/mds.29270
Scheltens, P., Blennow, K., Breteler, M. M. B., de Strooper, B., Frisoni, G. B., Salloway, S., & Van der Flier, W. M. (2016). Alzheimer’s disease. The Lancet, 388(10043), 505–517. https://doi.org/10.1016/S0140-6736(15)01124-1
Sheikh, S., Haque, E., & Mir, S. S. (2013). Neurodegenerative diseases: Multifactorial conformational diseases and their therapeutic interventions. Journal of Aging Research, 2013, 563481. https://doi.org/10.1155/2013/563481
Spillantini, M. G., Schmidt, M. L., Lee, V. M.-Y., Trojanowski, J. Q., Jakes, R., & Goedert, M. (1997). Alpha-synuclein in Lewy bodies. Nature, 388(6645), 839–840. https://doi.org/10.1038/42166
Stewart, T., Liu, C., Ginghina, C., Cain, K. C., Auinger, P., Cholerton, B., … Zhang, J. (2019). Pre-analytical differences in CSF biomarker measurements between ADNI and PPMI studies. Alzheimer’s & Dementia, 15(9), 1183–1192. https://doi.org/10.1016/j.jalz.2019.04.011
Thompson, A. G. B., Gray, E., Mäger, I., Thézénas, M.-L., Charles, P. D., Talbot, K., … Tabrizi, S. J. (2016). Extracellular vesicles in neurodegenerative disease. The Lancet Neurology, 15(3), 272–284. https://doi.org/10.1016/S1474-4422(15)00392-9
Tian, Y., Li, X., Wang, J., Wang, K., & Chen, Z. (2022). Blood extracellular vesicles carrying synaptic proteins as potential biomarkers for Alzheimer’s disease. Translational Neurodegeneration, 11, 29. https://doi.org/10.1186/s40035-022-00296-3
Wardlaw, J. M., Valdés Hernández, M. C., & Muñoz-Maniega, S. (2015). What are white matter hyperintensities made of?. Journal of the American Heart Association, 4(6), e001140. https://doi.org/10.1161/JAHA.114.001140
Wang, Y., & Mandelkow, E. (2016). Tau in physiology and pathology. Nature Reviews Neuroscience, 17(1), 5–21. https://doi.org/10.1038/nrn.2015
Mastrangelo, A., Mammana, A., Hall, S., Stomrud, E., Zenesini, C., Rossi, M., Janelidze, S., Ticca, A., Palmqvist, S., Magliocchetti, F., Baiardi, S., Mattsson, N., Hansson, O., & Parchi, P. (2024). Alpha-synuclein seed amplification assay longitudinal outcomes in Lewy body disease spectrum. Brain. https://doi.org/10.1093/brain/awae405
Lowes, H., Pyle, A., Santibanez-Koref, M., & Hudson, G. (2020). Circulating cell-free mitochondrial DNA levels in Parkinson’s disease are influenced by treatment. Molecular Neurodegeneration, 15(1), 10. https://doi.org/10.1186/S13024-020-00362-Y
Lowes, H., Pyle, A., Duddy, M., & Hudson, G. (2019). Cell-free mitochondrial DNA in progressive multiple sclerosis. Mitochondrion, 46, 307–312. https://doi.org/10.1016/j.mito.2018.07.008
Tian, C., Stewart, T., Hong, Z., Guo, Z.-G., Aro, P., Soltys, D., Pan, C., Peskind, E. R., Zabetian, C. P., Shaw, L. M., Galasko, D., Quinn, J. F., Shi, M., & Zhang, J. (2022). Blood extracellular vesicles carrying synaptic function‐ and brain‐related proteins as potential biomarkers for Alzheimer’s disease. Alzheimers & Dementia, 19(3), 909–923. https://doi.org/10.1002/alz.12723
Stewart, T., Shi, M., Mehrotra, A., Aro, P., Soltys, D., Kerr, K. F., Zabetian, C. P., Peskind, E. R., Taylor, P., Shaw, L. M., Trojanowski, J. Q., & Zhang, J. (2019). Impact of Pre-Analytical Differences on Biomarkers in the ADNI and PPMI Studies: Implications in the Era of Classifying Disease Based on Biomarkers. Journal of Alzheimer’s Disease, 69(1), 263–276. https://doi.org/10.3233/JAD-190069
Pedersen, C. C., Ushakova, A. Yu., Skogseth, R., Alves, G., Tysnes, O.-B., Aarsland, D., Lange, J., & Maple-Grødem, J. (2023). Inflammatory Biomarkers in Newly Diagnosed Patients With Parkinson Disease and Related Neurodegenerative Disorders. 10. https://doi.org/10.1212/NXI.0000000000200132
Tropea, T. F., Xie, S. X., Rick, J., Chahine, L. M., Dahodwala, N., Doshi, J., Davatzikos, C., Shaw, L. M., Van Deerlin, V. M., Trojanowski, J. Q., Weintraub, D., Weintraub, D., & Chen-Plotkin, A. (2018). APOE, thought disorder, and SPARE-AD predict cognitive decline in established Parkinson’s disease. Movement Disorders, 33(2), 289–297. https://doi.org/10.1002/MDS.27204
Shantaraman, A., Dammer, E. B., Ugochukwu, O., Duong, D. M., Yin, L., Carter, E. K., Gearing, M., Chen-Plotkin, A., Lee, E. B., Trojanowski, J., Bennett, D. A., Lah, J. J., Levey, A., Seyfried, N. T., & Higginbotham, L. (2024). Network proteomics of the Lewy body dementia brain reveals presynaptic signatures distinct from Alzheimer’s disease. Molecular Neurodegeneration, 19. https://doi.org/10.1186/s13024-024-00749-1
Soler-Sáez, I., Karz, A., Hidalgo, M. R., Gómez-Cabañes, B., López‐Cerdán, A., Català-Senent, J. F., Prutisto-Chang, K., Eskow, N. M., Izar, B., Redmer, T., Kumar, S., Davies, M. A., de la Iglesia-Vayá, M., Hernando, E., & García‐García, F. (2024). Unveiling common transcriptomic features between melanoma brain metastases and neurodegenerative diseases. Journal of Investigative Dermatology. https://doi.org/10.1016/j.jid.2024.09.005
Rennie, A., Ekman, U., Shams, S., Rydén, L., Samuelsson, J., Zettergren, A., Kern, S., Oppedal, K., Blanc, F., Hort, J., Garcia-Ptacek, S., Antonini, A., Lemstra, A. W., Padovani, A., Kramberger, M., Rektorová, I., Walker, Z., Snædal, J. G., Pardini, M., … Ferreira, D. (2024). Cerebrovascular and Alzheimer’s disease biomarkers in dementia with Lewy bodies and other dementias. Brain Communications. https://doi.org/10.1093/braincomms/fcae290
Skillbäck, T. B., Jönsson, L., Skoog, I., Blennow, K., Eriksdotter, M., Zetterberg, H., & Kern, S. (2025). Cerebrospinal Fluid Biomarkers for Alzheimer Disease Among Patients With Dementia. JAMA neurology, 82(6), 580–588. https://doi.org/10.1001/jamaneurol.2025.0693
Rahman, M. H., Akter, R., & Kamal, M. A. (2021). Prospective Function of Different Antioxidant Containing Natural Products in the Treatment of Neurodegenerative Diseases. Cns & Neurological Disorders-Drug Targets, 20(8), 694–703. https://doi.org/10.2174/1871527319666200722153611
Birba, A., Fittipaldi, S., Cediel Escobar, J. C., Gonzalez Campo, C., Legaz, A., Galiani, A., Díaz Rivera, M. N., Martorell Caro, M., Alifano, F., Piña-Escudero, S. D., Cardona, J. F., Neely, A., Forno, G., Carpinella, M., Slachevsky, A., Serrano, C., Sedeño, L., Ibáñez, A., & García, A. M. (2022). Multimodal Neurocognitive Markers of Naturalistic Discourse Typify Diverse Neurodegenerative Diseases. Cerebral cortex (New York, N.Y. : 1991), 32(16), 3377–3391. https://doi.org/10.1093/cercor/bhab421
Stoeck, K., Sánchez-Juan, P., Gawinecka, J., Green, A., Ladogana, A., Pocchiari, M., Sánchez-Valle, R., Mitrova, E., Sklaviadis, T., Kulczycki, J., Slivarichova, D., Saiz, A., Calero, M., Knight, R., Aguzzi, A., Laplanche, J.-L., Peoc’h, K., Schelzke, G., Karch, A., … Zerr, I. (2012). Cerebrospinal fluid biomarker supported diagnosis of Creutzfeldt–Jakob disease and rapid dementias: a longitudinal multicentre study over 10 years. Brain, 135(10), 3051–3061. https://doi.org/10.1093/BRAIN/AWS238
Reijs, B. L. R., Teunissen, C. E., Goncharenko, N., Betsou, F., Blennow, K., Baldeiras, I., Brosseron, F., Cavedo, E., Fladby, T., Fladby, T., Froelich, L., Gabryelewicz, T., Gurvit, H., Kapaki, E., Koson, P., Koson, P., Kulic, L., Lehmann, S., Lewczuk, P., … Visser, P. J. (2015). The Central Biobank and Virtual Biobank of BIOMARKAPD: A Resource for Studies on Neurodegenerative Diseases. Frontiers in Neurology, 6, 216. https://doi.org/10.3389/FNEUR.2015.00216
Skogseth, R., Skogseth, R., Hortobágyi, T., Hortobágyi, T., Soennesyn, H., Chwiszczuk, L. J., Ffytche, D., Rongve, A., Ballard, C., Ballard, C., Aarsland, D., & Aarsland, D. (2017). Accuracy of Clinical Diagnosis of Dementia with Lewy Bodies versus Neuropathology. Journal of Alzheimer’s Disease, 59(4), 1139–1152. https://doi.org/10.3233/JAD-170274
Bereczki, E., Francis, P. T., Howlett, D. R., Pereira, J. B., Höglund, K., Höglund, K., Bogstedt, A., Bogstedt, A., Cedazo-Minguez, A., Baek, J.-H., Hortobágyi, T., Attems, J., Ballard, C., & Aarsland, D. (2016). Synaptic proteins predict cognitive decline in Alzheimer’s disease and Lewy body dementia. Alzheimers & Dementia, 12(11), 1149–1158. https://doi.org/10.1016/J.JALZ.2016.04.005
Bruun, M., Frederiksen, K. S., Rhodius-Meester, H. F. M., Baroni, M., Gjerum, L., Koikkalainen, J., Urhemaa, T., Tolonen, A., van Gils, M., Tong, T., Guerrero, R., Rueckert, D., Dyremose, N., Andersen, B. B., Simonsen, A. H., Lemstra, A. W., Hallikainen, M., Kurl, S., Herukka, S.-K., … Hasselbalch, S. G. (2019). Impact of a Clinical Decision Support Tool on Dementia Diagnostics in Memory Clinics: The PredictND Validation Study. Current Alzheimer Research, 16(2), 91–101. https://doi.org/10.2174/1567205016666190103152425
Victor, K. G., Heffron, D. S., Sokolowski, J. D., Majumder, U., LeBlanc, A. C., & Mandell, J. (2018). Proteomic identification of synaptic caspase substrates. Synapse, 72(1). https://doi.org/10.1002/SYN.22014
Lloyd, J. J., Petrides, G., Donaghy, P. C., Colloby, S. J., Attems, J., O'Brien, J. T., Roberts, G., & Thomas, A. J. (2018). A new visual rating scale for Ioflupane imaging in Lewy body disease. NeuroImage. Clinical, 20, 823–829. https://doi.org/10.1016/j.nicl.2018.09.012
Ashton, N. J., Janelidze, S., Al Khleifat, A., Leuzy, A., van der Ende, E. L., Karikari, T. K., Benedet, A. L., Benedet, A. L., Pascoal, T. A., Pascoal, T. A., Lleo, A., Parnetti, L., Galimberti, D., Bonanni, L., Pilotto, A., Padovani, A., Lycke, J., Lycke, J., Novakova, L., … Hansson, O. (2021). A multicentre validation study of the diagnostic value of plasma neurofilament light. Nature Communications, 12(1), 3400. https://doi.org/10.1038/S41467-021-23620-Z
Buongiorno, M., Compta, Y., & Martí, M. J. (2011). Amyloid-β and τ biomarkers in Parkinson's disease-dementia. Journal of the neurological sciences, 310(1-2), 25–30. https://doi.org/10.1016/j.jns.2011.06.046
Shi, M., Bradner, J., Hancock, A. M., Chung, K. A., Quinn, J. F., Peskind, E. R., Galasko, D., Jankovic, J., Zabetian, C. P., Kim, H. M., Leverenz, J. B., Montine, T. J., Ginghina, C., Kang, U. J., Cain, K. C., Wang, Y., Aasly, J., Goldstein, D., & Zhang, J. (2011). Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression. Annals of neurology, 69(3), 570–580. https://doi.org/10.1002/ana.22311
Parnetti, L., Chiasserini, D., Bellomo, G., Giannandrea, D., De Carlo, C., Qureshi, M. M., Ardah, M. T., Varghese, S., Bonanni, L., Borroni, B., Tambasco, N., Eusebi, P., Rossi, A., Onofrj, M., Padovani, A., Calabresi, P., & El-Agnaf, O. M. A. (2011). Cerebrospinal fluid Tau/α-synuclein ratio in Parkinson’s disease and degenerative dementias†‡. Movement Disorders, 26(8), 1428–1435. https://doi.org/10.1002/MDS.23670
Wagshal, D., Sankaranarayanan, S., Guss, V., Hall, T., Berisha, F., Lobach, I., Karydas, A., Voltarelli, L., Scherling, C., Heuer, H. W., Tartaglia, M. C., Miller, Z. A., Coppola, G., Ahlijanian, M. K., Soares, H., Kramer, J. H., Rabinovici, G. D., Rosen, H. J., Miller, B. L., … Boxer, A. L. (2015). Divergent CSF τ alterations in two common tauopathies: Alzheimer’s disease and progressive supranuclear palsy. Journal of Neurology, Neurosurgery, and Psychiatry, 86(3), 244–250. https://doi.org/10.1136/JNNP-2014-308004
Toledo, J. B., Korff, A., Shaw, L. M., Trojanowski, J. Q., & Zhang, J. (2013). CSF α-synuclein improves diagnostic and prognostic performance of CSF tau and Aβ in Alzheimer’s disease. Acta Neuropathologica, 126(5), 683–697. https://doi.org/10.1007/S00401-013-1148-Z
Shill, H. A., Shill, H. A., Hentz, J. G., Caviness, J. N., Driver-Dunckley, E., Jacobson, S. A., Jacobson, S. A., Belden, C., Sabbagh, M. N., Sabbagh, M. N., Beach, T. G., & Adler, C. H. (2016). Unawareness of Hyposmia in Elderly People With and Without Parkinson’s Disease. Movement Disorders Clinical Practice, 3(1), 43–47. https://doi.org/10.1002/MDC3.12220
Skogseth, R., Skogseth, R., Hortobágyi, T., Hortobágyi, T., Soennesyn, H., Chwiszczuk, L. J., Ffytche, D., Rongve, A., Ballard, C., Ballard, C., Aarsland, D., & Aarsland, D. (2017). Accuracy of Clinical Diagnosis of Dementia with Lewy Bodies versus Neuropathology. Journal of Alzheimer’s Disease, 59(4), 1139–1152. https://doi.org/10.3233/JAD-170274
Starhof, C., Hejl, A.-M., Heegaard, N. H. H., Carlsen, A., Burton, M., Lilje, B., & Winge, K. (2018). The biomarker potential of cell‐free microRNA from cerebrospinal fluid in Parkinsonian Syndromes. Movement Disorders, 34. https://doi.org/10.1002/mds.27542
Dichev, V. D., Kazakova, M., & Sarafian, V. (2020). YKL-40 and neuron-specific enolase in neurodegeneration and neuroinflammation. Reviews in The Neurosciences, 31(5), 539–553. https://doi.org/10.1515/REVNEURO-2019-0100
Chiu, M.-J., Yang, S.-Y., Chen, T.-F., Lin, C.-H., Yang, F.-C., Chen, W.-P., Zetterberg, H., Zetterberg, H., Blennow, K., & Blennow, K. (2021). Synergistic Association between Plasma Aβ1-42 and p-tau in Alzheimer’s Disease but Not in Parkinson’s Disease or Frontotemporal Dementia. ACS Chemical Neuroscience, 12(8), 1376–1383. https://doi.org/10.1021/ACSCHEMNEURO.1C00010
Scaroni, F., Visconte, C., Serpente, M., Golia, M. T., Gabrielli, M., Huiskamp, M., Hulst, H. E., Carandini, T., De Riz, M., Pietroboni, A. M., Rotondo, E., Scarpini, E., Galimberti, D., Teunissen, C. E., van Dam, M., de Jong, B. A., Fenoglio, C., & Verderio, C. (2022). miR-150-5p and let-7b-5p in Blood Myeloid Extracellular Vesicles Track Cognitive Symptoms in Patients with Multiple Sclerosis. Cells, 11(9), 1551. https://doi.org/10.3390/cells11091551
Cavedoni, S., Chirico, A., Pedroli, E., Cipresso, P., & Riva, G. (2020). Digital Biomarkers for the Early Detection of Mild Cognitive Impairment: Artificial Intelligence Meets Virtual Reality. Frontiers in human neuroscience, 14, 245. https://doi.org/10.3389/fnhum.2020.00245
Kovac, D., Novakova, L., Mekyska, J., Novotny, K., Brabenec, L., Klobusiakova, P., & Rektorova, I. (2025). Digital speech biomarkers for assessing cognitive decline across neurodegenerative conditions. Computers in biology and medicine, 198(Pt B), 111251. https://doi.org/10.1016/j.compbiomed.2025.111251
Blennow, K., Hampel, H., Weiner, M., & Zetterberg, H. (2010). Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nature Reviews Neurology, 6(3), 131–144. https://doi.org/10.1038/nrneurol.2010.4
Brinkmalm, A., Brinkmalm, G., Honer, W. G., Frölich, L., Hausner, L., Minthon, L., … Zetterberg, H. (2014). SNAP-25 is a promising novel cerebrospinal fluid biomarker for synapse degeneration in Alzheimer’s disease. Molecular Neurodegeneration, 9, 53. https://doi.org/10.1186/1750-1326-9-53
Frisoni, G. B., Fox, N. C., Jack, C. R., Scheltens, P., & Thompson, P. M. (2010). The clinical use of structural MRI in Alzheimer disease. Nature Reviews Neurology, 6(2), 67–77. https://doi.org/10.1038/nrneurol.2009.215
Gaetani, L., Blennow, K., Calabresi, P., Di Filippo, M., Parnetti, L., & Zetterberg, H. (2019). Neurofilament light chain as a biomarker in neurological disorders. Journal of Neurology, Neurosurgery & Psychiatry, 90(8), 870–881. https://doi.org/10.1136/jnnp-2018-320106
Hardy, J., & Selkoe, D. J. (2002). The amyloid hypothesis of Alzheimer’s disease: Progress and problems on the road to therapeutics. Science, 297(5580), 353–356. https://doi.org/10.1126/science.1072994
Jack, C. R., Bennett, D. A., Blennow, K., Carrillo, M. C., Dunn, B., Haeberlein, S. B., … Silverberg, N. (2018). NIA-AA research framework: Toward a biological definition of Alzheimer’s disease. Alzheimer’s & Dementia, 14(4), 535–562. https://doi.org/10.1016/j.jalz.2018.02.018
Janelidze, S., Mattsson, N., Palmqvist, S., Smith, R., Beach, T. G., Serrano, G. E., … Hansson, O. (2020). Plasma P-tau181 in Alzheimer’s disease. Nature Medicine, 26(3), 379–386. https://doi.org/10.1038/s41591-020-0755-1
Liu, C.-C., Kanekiyo, T., Xu, H., & Bu, G. (2013). Apolipoprotein E and Alzheimer disease: Risk, mechanisms and therapy. Nature Reviews Neurology, 9(2), 106–118. https://doi.org/10.1038/nrneurol.2012.263
Lowes, H., Pyle, A., Duddy, M., Hudson, G., & Chinnery, P. F. (2019). Reduced circulating cell-free mitochondrial DNA is associated with neurodegeneration. Annals of Clinical and Translational Neurology, 6(6), 1094–1102. https://doi.org/10.1002/acn3.782
Lowes, H., Pyle, A., Duddy, M., Hudson, G., & Chinnery, P. F. (2020). Cell-free mitochondrial DNA in disease. Clinical Chemistry, 66(2), 249–256. https://doi.org/10.1093/clinchem/hvz029
Mastrangelo, A., Rossi, M., Baiardi, S., Zenesini, C., Capellari, S., & Parchi, P. (2024). α-Synuclein seed amplification assay parameters correlate with disease stage and dementia in Lewy body disease. Acta Neuropathologica, 147, 45–60. https://doi.org/10.1007/s00401-023-02658-7
Pedersen, A. L., Eriksson, J. E., Nilsson, J., Bäckström, D., Blennow, K., Zetterberg, H., & Svenningsson, P. (2023). Inflammatory biomarker panels identified using proximity extension assays distinguish Parkinson’s disease and Alzheimer’s disease. Movement Disorders, 38(4), 612–624. https://doi.org/10.1002/mds.29270
Scheltens, P., Blennow, K., Breteler, M. M. B., de Strooper, B., Frisoni, G. B., Salloway, S., & Van der Flier, W. M. (2016). Alzheimer’s disease. The Lancet, 388(10043), 505–517. https://doi.org/10.1016/S0140-6736(15)01124-1
Sheikh, S., Haque, E., & Mir, S. S. (2013). Neurodegenerative diseases: Multifactorial conformational diseases and their therapeutic interventions. Journal of Aging Research, 2013, 563481. https://doi.org/10.1155/2013/563481
Spillantini, M. G., Schmidt, M. L., Lee, V. M.-Y., Trojanowski, J. Q., Jakes, R., & Goedert, M. (1997). Alpha-synuclein in Lewy bodies. Nature, 388(6645), 839–840. https://doi.org/10.1038/42166
Stewart, T., Liu, C., Ginghina, C., Cain, K. C., Auinger, P., Cholerton, B., … Zhang, J. (2019). Pre-analytical differences in CSF biomarker measurements between ADNI and PPMI studies. Alzheimer’s & Dementia, 15(9), 1183–1192. https://doi.org/10.1016/j.jalz.2019.04.011
Thompson, A. G. B., Gray, E., Mäger, I., Thézénas, M.-L., Charles, P. D., Talbot, K., … Tabrizi, S. J. (2016). Extracellular vesicles in neurodegenerative disease. The Lancet Neurology, 15(3), 272–284. https://doi.org/10.1016/S1474-4422(15)00392-9
Tian, Y., Li, X., Wang, J., Wang, K., & Chen, Z. (2022). Blood extracellular vesicles carrying synaptic proteins as potential biomarkers for Alzheimer’s disease. Translational Neurodegeneration, 11, 29. https://doi.org/10.1186/s40035-022-00296-3
Wardlaw, J. M., Valdés Hernández, M. C., & Muñoz-Maniega, S. (2015). What are white matter hyperintensities made of?. Journal of the American Heart Association, 4(6), e001140. https://doi.org/10.1161/JAHA.114.001140
Wang, Y., & Mandelkow, E. (2016). Tau in physiology and pathology. Nature Reviews Neuroscience, 17(1), 5–21. https://doi.org/10.1038/nrn.2015
Mastrangelo, A., Mammana, A., Hall, S., Stomrud, E., Zenesini, C., Rossi, M., Janelidze, S., Ticca, A., Palmqvist, S., Magliocchetti, F., Baiardi, S., Mattsson, N., Hansson, O., & Parchi, P. (2024). Alpha-synuclein seed amplification assay longitudinal outcomes in Lewy body disease spectrum. Brain. https://doi.org/10.1093/brain/awae405
Lowes, H., Pyle, A., Santibanez-Koref, M., & Hudson, G. (2020). Circulating cell-free mitochondrial DNA levels in Parkinson’s disease are influenced by treatment. Molecular Neurodegeneration, 15(1), 10. https://doi.org/10.1186/S13024-020-00362-Y
Lowes, H., Pyle, A., Duddy, M., & Hudson, G. (2019). Cell-free mitochondrial DNA in progressive multiple sclerosis. Mitochondrion, 46, 307–312. https://doi.org/10.1016/j.mito.2018.07.008
Tian, C., Stewart, T., Hong, Z., Guo, Z.-G., Aro, P., Soltys, D., Pan, C., Peskind, E. R., Zabetian, C. P., Shaw, L. M., Galasko, D., Quinn, J. F., Shi, M., & Zhang, J. (2022). Blood extracellular vesicles carrying synaptic function‐ and brain‐related proteins as potential biomarkers for Alzheimer’s disease. Alzheimers & Dementia, 19(3), 909–923. https://doi.org/10.1002/alz.12723
Stewart, T., Shi, M., Mehrotra, A., Aro, P., Soltys, D., Kerr, K. F., Zabetian, C. P., Peskind, E. R., Taylor, P., Shaw, L. M., Trojanowski, J. Q., & Zhang, J. (2019). Impact of Pre-Analytical Differences on Biomarkers in the ADNI and PPMI Studies: Implications in the Era of Classifying Disease Based on Biomarkers. Journal of Alzheimer’s Disease, 69(1), 263–276. https://doi.org/10.3233/JAD-190069
Pedersen, C. C., Ushakova, A. Yu., Skogseth, R., Alves, G., Tysnes, O.-B., Aarsland, D., Lange, J., & Maple-Grødem, J. (2023). Inflammatory Biomarkers in Newly Diagnosed Patients With Parkinson Disease and Related Neurodegenerative Disorders. 10. https://doi.org/10.1212/NXI.0000000000200132
Tropea, T. F., Xie, S. X., Rick, J., Chahine, L. M., Dahodwala, N., Doshi, J., Davatzikos, C., Shaw, L. M., Van Deerlin, V. M., Trojanowski, J. Q., Weintraub, D., Weintraub, D., & Chen-Plotkin, A. (2018). APOE, thought disorder, and SPARE-AD predict cognitive decline in established Parkinson’s disease. Movement Disorders, 33(2), 289–297. https://doi.org/10.1002/MDS.27204
Shantaraman, A., Dammer, E. B., Ugochukwu, O., Duong, D. M., Yin, L., Carter, E. K., Gearing, M., Chen-Plotkin, A., Lee, E. B., Trojanowski, J., Bennett, D. A., Lah, J. J., Levey, A., Seyfried, N. T., & Higginbotham, L. (2024). Network proteomics of the Lewy body dementia brain reveals presynaptic signatures distinct from Alzheimer’s disease. Molecular Neurodegeneration, 19. https://doi.org/10.1186/s13024-024-00749-1
Soler-Sáez, I., Karz, A., Hidalgo, M. R., Gómez-Cabañes, B., López‐Cerdán, A., Català-Senent, J. F., Prutisto-Chang, K., Eskow, N. M., Izar, B., Redmer, T., Kumar, S., Davies, M. A., de la Iglesia-Vayá, M., Hernando, E., & García‐García, F. (2024). Unveiling common transcriptomic features between melanoma brain metastases and neurodegenerative diseases. Journal of Investigative Dermatology. https://doi.org/10.1016/j.jid.2024.09.005
Rennie, A., Ekman, U., Shams, S., Rydén, L., Samuelsson, J., Zettergren, A., Kern, S., Oppedal, K., Blanc, F., Hort, J., Garcia-Ptacek, S., Antonini, A., Lemstra, A. W., Padovani, A., Kramberger, M., Rektorová, I., Walker, Z., Snædal, J. G., Pardini, M., … Ferreira, D. (2024). Cerebrovascular and Alzheimer’s disease biomarkers in dementia with Lewy bodies and other dementias. Brain Communications. https://doi.org/10.1093/braincomms/fcae290
Skillbäck, T. B., Jönsson, L., Skoog, I., Blennow, K., Eriksdotter, M., Zetterberg, H., & Kern, S. (2025). Cerebrospinal Fluid Biomarkers for Alzheimer Disease Among Patients With Dementia. JAMA neurology, 82(6), 580–588. https://doi.org/10.1001/jamaneurol.2025.0693
Rahman, M. H., Akter, R., & Kamal, M. A. (2021). Prospective Function of Different Antioxidant Containing Natural Products in the Treatment of Neurodegenerative Diseases. Cns & Neurological Disorders-Drug Targets, 20(8), 694–703. https://doi.org/10.2174/1871527319666200722153611
Birba, A., Fittipaldi, S., Cediel Escobar, J. C., Gonzalez Campo, C., Legaz, A., Galiani, A., Díaz Rivera, M. N., Martorell Caro, M., Alifano, F., Piña-Escudero, S. D., Cardona, J. F., Neely, A., Forno, G., Carpinella, M., Slachevsky, A., Serrano, C., Sedeño, L., Ibáñez, A., & García, A. M. (2022). Multimodal Neurocognitive Markers of Naturalistic Discourse Typify Diverse Neurodegenerative Diseases. Cerebral cortex (New York, N.Y. : 1991), 32(16), 3377–3391. https://doi.org/10.1093/cercor/bhab421
Stoeck, K., Sánchez-Juan, P., Gawinecka, J., Green, A., Ladogana, A., Pocchiari, M., Sánchez-Valle, R., Mitrova, E., Sklaviadis, T., Kulczycki, J., Slivarichova, D., Saiz, A., Calero, M., Knight, R., Aguzzi, A., Laplanche, J.-L., Peoc’h, K., Schelzke, G., Karch, A., … Zerr, I. (2012). Cerebrospinal fluid biomarker supported diagnosis of Creutzfeldt–Jakob disease and rapid dementias: a longitudinal multicentre study over 10 years. Brain, 135(10), 3051–3061. https://doi.org/10.1093/BRAIN/AWS238
Reijs, B. L. R., Teunissen, C. E., Goncharenko, N., Betsou, F., Blennow, K., Baldeiras, I., Brosseron, F., Cavedo, E., Fladby, T., Fladby, T., Froelich, L., Gabryelewicz, T., Gurvit, H., Kapaki, E., Koson, P., Koson, P., Kulic, L., Lehmann, S., Lewczuk, P., … Visser, P. J. (2015). The Central Biobank and Virtual Biobank of BIOMARKAPD: A Resource for Studies on Neurodegenerative Diseases. Frontiers in Neurology, 6, 216. https://doi.org/10.3389/FNEUR.2015.00216
Skogseth, R., Skogseth, R., Hortobágyi, T., Hortobágyi, T., Soennesyn, H., Chwiszczuk, L. J., Ffytche, D., Rongve, A., Ballard, C., Ballard, C., Aarsland, D., & Aarsland, D. (2017). Accuracy of Clinical Diagnosis of Dementia with Lewy Bodies versus Neuropathology. Journal of Alzheimer’s Disease, 59(4), 1139–1152. https://doi.org/10.3233/JAD-170274
Bereczki, E., Francis, P. T., Howlett, D. R., Pereira, J. B., Höglund, K., Höglund, K., Bogstedt, A., Bogstedt, A., Cedazo-Minguez, A., Baek, J.-H., Hortobágyi, T., Attems, J., Ballard, C., & Aarsland, D. (2016). Synaptic proteins predict cognitive decline in Alzheimer’s disease and Lewy body dementia. Alzheimers & Dementia, 12(11), 1149–1158. https://doi.org/10.1016/J.JALZ.2016.04.005
Bruun, M., Frederiksen, K. S., Rhodius-Meester, H. F. M., Baroni, M., Gjerum, L., Koikkalainen, J., Urhemaa, T., Tolonen, A., van Gils, M., Tong, T., Guerrero, R., Rueckert, D., Dyremose, N., Andersen, B. B., Simonsen, A. H., Lemstra, A. W., Hallikainen, M., Kurl, S., Herukka, S.-K., … Hasselbalch, S. G. (2019). Impact of a Clinical Decision Support Tool on Dementia Diagnostics in Memory Clinics: The PredictND Validation Study. Current Alzheimer Research, 16(2), 91–101. https://doi.org/10.2174/1567205016666190103152425
Victor, K. G., Heffron, D. S., Sokolowski, J. D., Majumder, U., LeBlanc, A. C., & Mandell, J. (2018). Proteomic identification of synaptic caspase substrates. Synapse, 72(1). https://doi.org/10.1002/SYN.22014
Lloyd, J. J., Petrides, G., Donaghy, P. C., Colloby, S. J., Attems, J., O'Brien, J. T., Roberts, G., & Thomas, A. J. (2018). A new visual rating scale for Ioflupane imaging in Lewy body disease. NeuroImage. Clinical, 20, 823–829. https://doi.org/10.1016/j.nicl.2018.09.012
Ashton, N. J., Janelidze, S., Al Khleifat, A., Leuzy, A., van der Ende, E. L., Karikari, T. K., Benedet, A. L., Benedet, A. L., Pascoal, T. A., Pascoal, T. A., Lleo, A., Parnetti, L., Galimberti, D., Bonanni, L., Pilotto, A., Padovani, A., Lycke, J., Lycke, J., Novakova, L., … Hansson, O. (2021). A multicentre validation study of the diagnostic value of plasma neurofilament light. Nature Communications, 12(1), 3400. https://doi.org/10.1038/S41467-021-23620-Z
Buongiorno, M., Compta, Y., & Martí, M. J. (2011). Amyloid-β and τ biomarkers in Parkinson's disease-dementia. Journal of the neurological sciences, 310(1-2), 25–30. https://doi.org/10.1016/j.jns.2011.06.046
Shi, M., Bradner, J., Hancock, A. M., Chung, K. A., Quinn, J. F., Peskind, E. R., Galasko, D., Jankovic, J., Zabetian, C. P., Kim, H. M., Leverenz, J. B., Montine, T. J., Ginghina, C., Kang, U. J., Cain, K. C., Wang, Y., Aasly, J., Goldstein, D., & Zhang, J. (2011). Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression. Annals of neurology, 69(3), 570–580. https://doi.org/10.1002/ana.22311
Published
2026-02-23
How to Cite
Ravindra Kumar, A. (2026). Biomarkers in Neurodegenerative Diseases: A Bibliometric Analysis Using VOSviewer. International Journal of Social Science Research and Review, 9(3), 126-146. https://doi.org/10.47814/ijssrr.v9i3.3279
Section
Main Articles
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Copyright for this article is retained by the author(s), with first publication rights granted to the journal. This is an open-access article distributed under the terms and conditions of the Creative Commons Attribution license (https://creativecommons.org/licenses/by-nc-nd/4.0/).
